www673454d7

DeepWork Leads Oversubscribed $22M Series A-1

Tue, 03 Mar 2026 20:56:13 GMT

FirmPilot Closes Oversubscribed $22M Series A-1 to Scale AI-Powered Legal Marketing Platform

FirmPilot, the AI-powered legal marketing platform, today announced the close of its oversubscribed Series A-1 funding round. The round was led by DeepWork Capital, with a significant investment from Data Point Capital, and participation from existing investors including Blumberg Capital, Thomson Reuters Ventures, Valor Ventures, SaaS Ventures, and EarlyLight Ventures. The new capital brings FirmPilot's total funding to $27.25M. As part of the investment, DeepWork Capital Partner Ken Hall will join FirmPilot's Board of Directors.

Every hour, more than 1,000 people in the U.S. search online for legal help, yet 75% never scroll past the first page of results. For the 425,000+ law firms in the U.S., legacy approaches to marketing, retaining traditional agencies, manually managing ad spend, and relying on guesswork are costly, low-ROI, and not built for busy legal professionals. FirmPilot's patent-pending AI Legal Marketing Engine replaces this guesswork with intelligence, using proprietary data and AI to help law firms attract higher-value clients, faster.

Source: https://www.prnewswire.com/news-releases/firmpilot-closes-oversubscribed-22m-series-a-1-to-scale-ai-powered-legal-marketing-platform-302697703.html

Urban SDK Raises $65M Growth Round

Mon, 16 Feb 2026 12:40:58 GMT

Urban SDK, equipping local and state governments across the nation with geospatial AI that empowers decisive action with precision and efficiency, today announced a $65M growth funding investment from Riverwood Capital, one of the leading investment firms solely dedicated to technology growth and scalability. This investment fuels Urban SDK’s rapid growth across the public sector as a category-defining leader, providing the system of action for over 300 civic leaders in 40 states to optimize their resources for smarter, data-driven operations that address cities’ emerging safety and infrastructure needs.

Urban SDK’s tools enable cities, states and Departments of Transportation (DOTs) to efficiently deploy limited public resources to best serve and safeguard their constituents. The company’s geospatial AI capabilities have wide applications, from helping local governments address everyday concerns like citizen complaints and traffic enforcement, to assisting in emergency operations by helping them respond to natural disasters. With cities allocating 70% of general fund budgets to public safety and community well-being, while dedicating precious resources to efficient critical solutions, governments that work with Urban SDK are able to preserve resources and accomplish more by streamlining daily operations into a single platform.

“Our mission has always been to equip the government teams serving our communities with the intelligence they need to protect lives and steward public resources responsibly,” said Drew Messer, Co-founder and CEO, Urban SDK. “Today, hundreds of cities use Urban SDK to prevent traffic accidents and fatalities and to make smarter decisions, at roughly ten cents on the dollar versus traditional approaches. Riverwood Capital’s partnership allows us to scale our AI system of action for these governments and civil leaders, accelerating our ability to help communities build safer, more resilient cities.”

TENEX.AI Announces Investment from DTCP, Expansion in EMEA Market

Tue, 02 Dec 2025 14:40:34 GMT

TENEX.AI, the AI-native cybersecurity company transforming security operations, today announced additional investment in its $27 million Series A funding round from DTCP. This follows previous closes led by Crosspoint Capital Partners, with full participation from Andreessen Horowitz (a16z), Shield Capital, DeepWork Capital, and the Florida Opportunity Fund.

In just three quarters in the market, TENEX has exceeded $18 million in revenue and secured multiple Fortune 500 customers, underscoring TENEX’s leadership in the AI SOC and MDR markets. The investment supports its official expansion into the EMEA market, where TENEX anticipates establishing a physical international headquarters and scaling its EMEA team across 2026 to meet surging demand for AI-driven threat detection and response.

Founded in 2015, DTCP is a global investment management firm with over €3 billion in assets under management and a team of more than 60 professionals across Europe, San Francisco, and Tel Aviv. DTCP backs the builders of the digital world — investing in the technologies and infrastructure that connect, compute, and power modern life. This partnership strengthens TENEX’s ability to deliver innovative, scalable security solutions tailored to EMEA enterprises facing evolving cyber threats.

As part of this strategic funding, TENEX is officially entering the EMEA market, with plans to establish a dedicated physical international headquarters and rapidly expand its regional team throughout 2026. While location and further specifics will be announced in the coming months, the move signals TENEX’s ambitious vision to become a cornerstone of Europe’s cybersecurity landscape, leveraging the region’s robust tech ecosystem, regulatory frameworks like the EU AI Act, and collaborative initiatives such as the European Cyber Security Organisation (ECSO).

This expansion not only enhances TENEX’s global footprint but also positions the company to address the unique cyber threats facing EMEA organizations, including converging threat groups as highlighted in the ENISA Threat Landscape 2025 report, rising ransomware attacks noted in Microsoft’s Digital Defense Report 2025, and the projected 12.42% CAGR growth in Europe’s cybersecurity market through 2033. By contributing to initiatives like ReArm Europe for collaborative R&D, TENEX aims to drive innovation, job creation, and resilient digital infrastructure across the continent.

TENEX CEO Eric Foster announced: “This investment from DTCP propels our global mission forward, enabling us to bring AI-native MDR to the dynamic EMEA market. By establishing our international headquarters here, we’re tapping into Europe’s talent in AI and cybersecurity, while upholding the moral imperative to combat the evil of cybercrime and give good the advantage as we safeguard our allies’ critical infrastructure against sophisticated threats. With team growth across 2026 and exponential advancements in our U.S. operations, TENEX is committed to empowering businesses to innovate securely, fostering the next generation of cyber defenders on a worldwide scale.”

TENEX’s alignment with the EMEA tech ecosystem is further evidenced by key 2025 trends, such as the World Economic Forum’s Global Cybersecurity Outlook emphasizing collaborative risk management, PwC’s identification of AI agents as a top trend for EMEA, and Aon’s insights on navigating cyber risks amid AI-driven competitiveness projects involving over 60 major European companies. These developments underscore the region’s momentum in fostering trustworthy AI and cybersecurity innovations, which TENEX is poised to advance through its agentic AI platform, integrating seamlessly with cloud-native environments to deliver unprecedented threat agility.

This announced funding will accelerate TENEX’s engineering efforts to enhance its agentic AI capabilities, expand sales to meet growing international demand, and support its enterprise customers with faster, more cost-effective threat detection and response.

“DTCP is thrilled to partner with TENEX as they pioneer AI-native security operations in EMEA and beyond,” said Lance Matthews, Partner at DTCP. “Their explosive growth and innovative approach to fusing AI with human expertise align perfectly with our focus on digital transformation, positioning them to redefine enterprise protection in a high-stakes landscape. We’re excited to support their EMEA expansion, which will leverage Europe’s AI talent and regulatory strengths to deliver scalable security solutions amid rising threats.”

Source: https://tenex.ai/tenex-ai-dtcp-emea/

Exowatt Announces $50M Funding Round - Profiled by TechCrunch

Thu, 13 Nov 2025 14:29:36 GMT

Sam Altman-backed Exowatt wants to power AI data centers with billions of hot rocks

When Hannan Happi started thinking about how to solve the AI power crisis, he kept one figure in mind: one cent per kilowatt-hour. “We went through all sorts of configurations and designs,” Happi, co-founder and CEO of Exowatt, told TechCrunch. “They all look different from each other. We tried to learn from every one of them: How do I reduce structural costs? How do I reduce maintenance costs? How do I optimize for this?”

After years of brainstorming and building, Exowatt’s first step toward that goal is a simple box the size of a shipping container topped with a clear awning. Inside is similarly simple. If Exowatt can deliver on its promise of delivering cheap solar power that generates electricity 24-7, it could upend the data center market and broader energy world, delivering round-the-clock power at very low cost.

To scale production in pursuit of the one-cent per kWh target, Exowatt has raised an additional $50 million in an extension to its $70 million Series A round that closed in April, TechCrunch has exclusively learned.

The extension was led by MVP Ventures and 8090 Industries with participation from Atomic, BAM, Bay Bridge Ventures, DeepWork Capital, Dragon Global, the Florida Opportunity Fund, Massive VC, New Atlas Capital, Overmatch, Protagonist, and StepStone. Previous investors include Andreessen Horowitz and Sam Altman.

Source: https://techcrunch.com/2025/11/13/sam-atlman-backed-exowatt-wants-to-power-ai-data-centers-with-billions-of-hot-rocks/

Enhesa Acquires TotalSDS

Mon, 27 Oct 2025 19:18:45 GMT

Creating a connected, end-to-end workflow for global chemical compliance and operations management.

Enhesa, the leading provider of regulatory business intelligence worldwide, today announced the acquisition of TotalSDS, a specialist provider of Safety Data Sheet (SDS) authoring software. The acquisition builds on Enhesa’s leadership position in product compliance, EHS intelligence and sustainable chemistry solutions. By integrating TotalSDS’ software and solutions, Enhesa will create an end-to-end workflow for the management of chemical safety data, allowing chemical manufacturers, formulators and distributors in the chemicals supply chain to stay compliant with complex and constantly changing global regulatory requirements.

A pioneer in the field of software-driven SDS authoring and management, TotalSDS helps companies efficiently produce compliant chemical safety documentation and manage ongoing updates and dissemination of that documentation to key stakeholders. SDS are foundational building blocks to workplace safety containing detailed information on the chemical composition of products, including required disclosures on chemicals and chemical compounds that could harm workers. Currently, more than 83 countries require potentially harmful chemicals to be accompanied by SDS following a detailed standard for classification, labeling and record-keeping. Though many countries have adopted global requirements such as a Globally Harmonized System (GHS) for tracking and cataloging this information, details vary widely in each jurisdiction and reporting requirements are continually revised on a chemical-by-chemical basis.

“SDS authoring and management is a complex, labor- and-detail-intensive process that many companies are still managing with printed documents stored in binders. Global regulatory reporting requirements demand that everyone in the hazardous chemicals supply chain should have the ability to produce and store real-time updates to their SDS based on changes in chemical formulation, hazard classification and different regional regulatory requirements – that is not something that can be reliably tracked on paper,” said Peter Schramme, CEO at Enhesa. “TotalSDS has pioneered the digital transformation of the SDS workflow, and that expertise is the perfect complement to our market-leading regulatory content and hazard intelligence.”

Source: https://www.enhesa.com/resources/press/enhesa-acquires-totalsds/

TENEX.AI Secures Funding from Florida Opportunity Fund & DeepWork Capital, Sets World HQ in Sarasota FL

Mon, 27 Oct 2025 14:24:30 GMT

TENEX.AI, the AI-native cybersecurity company transforming security operations, today announced additional investment in its $27 million Series A funding round from DeepWork Capital and the Florida Opportunity Fund. This follows the initial close led by Crosspoint Capital Partners, with full participation from Andreessen Horowitz (a16z) and Shield Capital.

This follows the initial close led by Crosspoint Capital Partners, with full participation from Andreessen Horowitz (a16z) and Shield Capital.

In just six months in the market, TENEX has exceeded $10 million in revenue and secured multiple Fortune 500 customers, underscoring TENEX’s leadership in the AI SOC and MDR markets. The investment supports its commitment to establishing its world headquarters in Sarasota, FL, aligning with regional initiatives to bolster Florida’s already strong cybersecurity ecosystem.

DeepWork Capital, an Orlando-based early-stage venture capital firm founded in 2015, invests in innovative companies in the technology and life science sectors through both proprietary and public committed capital funds. The Florida Opportunity Fund, a state-backed initiative promoting economic growth through targeted investments, has approved over $250 million in loans and investments for Florida businesses via programs like SSBCI 2.0. Together, these investors strengthen TENEX’s ties to Florida’s innovation landscape.

As part of this investment, TENEX is opening its world headquarters in Sarasota, FL, in alignment with the emergence of CyberBay – Tampa Bay’s thriving cybersecurity ecosystem that ties together workforce development, the private sector, and military and government initiatives. Recent CyberBay milestones include an inaugural conference hosted by Cyber Florida, the Bellini College of Artificial Intelligence and Cybersecurity at USF, and Bellini Capital. The October event followed the historic $40 million gift that established the Bellini College earlier this year. TENEX anticipates hiring up to 100 high-skilled AI and cybersecurity employees in Sarasota over the next couple of years, with proportional growth in its other offices in Kansas City, and San Jose, CA.

Source: https://tenex.ai/tenex-florida-opportunity-fund-sarasota-headquarters/?v=li

Myosin Therapeutics Receives FDA Fast Track Designation for MT-125 in Glioblastoma

Wed, 22 Oct 2025 14:23:10 GMT

Myosin Therapeutics Receives FDA Fast Track Designation for MT-125 in Glioblastoma

Myosin Therapeutics, Inc., a clinical-stage biotechnology company developing first-in-class therapies that modulate molecular motor proteins, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to MT-125 for the treatment of glioblastoma (GBM).

Fast Track is an FDA program designed to facilitate development and expedite review of drugs that treat serious conditions and address unmet medical needs. This designation benefits patients and drug sponsors by enabling more frequent interactions with the FDA and providing eligibility for rolling review of a marketing application.

"Receiving Fast Track designation validates our conviction that MT-125 has the potential to offer an entirely novel treatment approach to patients with even the most aggressive forms of glioblastoma," said Dr. Courtney Miller, Chief Executive Officer of Myosin Therapeutics. "We are energized by the open communication with the FDA that the Fast Track offers because it will ensure we advance MT-125 as quickly as possible with our patient-centered approach."

Source: https://www.prnewswire.com/news-releases/myosin-therapeutics-receives-fda-fast-track-designation-for-mt-125-in-glioblastoma-302591816.html

Irys Raises $12.5 Million to Expand AI-Native Insurance Platform

Mon, 13 Oct 2025 14:21:44 GMT

Investors Back Irys Insurtech with $12.5 Million to Reinvent Insurance Software

Irys, the company rebuilding insurance infrastructure from the ground up, today announced a $12.5 million seed round led by Markd, with participation from Deepwork Capital, Florida Opportunity Fund, Ansay & Associates, HICO Ventures, and JMG Capital.

The round gives Irys fresh capital to expand engineering, accelerate implementation, and scale distribution partnerships across the U.S and Canada. It also underscores a resurgence of investor confidence in insurance infrastructure, coming shortly after Markd's own $500 million fundraise to back transformative insurtechs.

"For 15 years I ran agencies on tech that didn't care if it was usable," said Margeaux Giles, CEO of Irys. "The industry's been trapped in contracts, broken platforms, and empty promises. It's eroded the trust agents fight to build every day with their clients. Irys is how we fix that."

Source: https://www.prnewswire.com/news-releases/investors-back-irys-insurtech-with-12-5-million-to-reinvent-insurance-software-302581215.html

Circuitry.ai Closes Seed Funding

Thu, 02 Oct 2025 14:20:12 GMT

Circuitry.ai, a Tampa, FL-based decision intelligence company enabling Autonomous Service Journeys for manufacturers of complex and mission-critical equipment, closed its seed financing round of undisclosed amount.

The round was led by DeepWork Capital with participation from Florida Opportunity Fund, Lasagna, and Lookout Ventures. DeepWork Capital’s Ben Patz will join Circuitry.ai’s Board of Directors.

The company intends to use the funds to expand its go-to-market and engineering teams, deepen integrations with service management platforms, and extend its Autonomous Service Journey framework to more customers in industries such as automotive, heavy equipment, industrial systems, HVAC, and medical devices.

Led by Ashok Kartham, Founder & CEO, Circuitry.ai Circuitry.ai delivers an advanced Service Decision Intelligence platform and enterprise AI as a Service (AIaaS) applications specifically designed for manufacturers to enhance service outcomes. By combining AI-driven knowledge, analytics, and automation, Circuitry.ai transforms complex service lifecycle data into precise answers, accurate recommendations, and actionable insights. Its AI workers, including Product Advisor, Service Advisor, Parts Advisor, and Warranty Specialist, significantly boost productivity, increase first-time fix rates, and drive profitable growth through autonomous decision-making.

Source: https://www.citybiz.co/article/753858/circuitry-ai-closes-seed-funding/

Cardurion Pharmaceuticals Completes Enrollment in Phase 2 CYCLE Trials Evaluating CRD-750, a Novel PDE9 inhibitor, in Heart Failure

Wed, 06 Aug 2025 14:07:16 GMT

Cardurion Pharmaceuticals, Inc. (“Cardurion”), a clinical-stage biotechnology company discovering and developing new therapeutic approaches for the treatment of patients with cardiovascular diseases, today announced that it has completed enrollment in two global, multi-center, Phase 2 clinical trials assessing the safety and efficacy of CRD-750 in both types of chronic heart failure (HFrEF and HFpEF).

CRD-750 is an orally-administered phosphodiesterase 9 (PDE9) inhibitor that represents a new mechanism to enhance the natriuretic peptide signaling (NPS) pathway, a clinically-validated pathway for the treatment of patients with heart failure. Cardurion is the first company to bring a PDE9 inhibitor into clinical development for the treatment of chronic heart failure.

The CYCLE-1-REF trial (NCT06215911) enrolled approximately 560 patients with HFrEF and is evaluating three doses of CRD-750 compared to placebo. CYCLE-2-PEF (NCT06215586) enrolled approximately 300 patients with HFpEF and is evaluating one dose of CRD-750 compared to placebo. The primary endpoint of both CYCLE clinical trials is the change in N-terminal pro-B-type natriuretic peptide (NT-proBNP), a peptide that is released by the heart in the setting of heart failure. Reduction in NT-proBNP has been used as a biomarker to measure the treatment effect in clinical trials of other approved heart failure therapies. The trials are also evaluating secondary endpoints, including additional biomarkers and the Kansas City Cardiomyopathy Questionnaire (KCCQ), a patient-reported outcomes scale.

“The clinical community eagerly awaits the results of the CYCLE clinical trials. Despite recent approvals, a large unmet medical need persists and patients with heart failure continue to experience high rates of morbidity and mortality. PDE9 inhibition is a promising new mechanism in the NPS pathway that may offer an opportunity to improve the standard of care treatment for the millions of patients with both types of chronic heart failure,” said James Udelson, MD, Chief of Cardiology at Tufts Medical Center and Principal Investigator for the CYCLE-1-REF and CYCLE-2-PEF trials.

“Completion of enrollment in the CYCLE trials represents a major milestone in our CRD-750 clinical program. Since the founding of Cardurion, our team has believed that the upregulation of PDE9 that occurs in heart failure is a critical element limiting the beneficial clinical effects of the highly validated NPS pathway. Our progress brings us closer to our goal of leveraging PDE9 inhibition to address unmet needs for patients,” said Howard Surks, MD, Chief Medical and Scientific Officer of Cardurion. “It is gratifying for us to implement this large, global clinical program in partnership with the cardiovascular treatment community. We look forward to receiving the Phase 2 results from these clinical trials and presenting them at a future medical meeting.”

Source: https://www.globenewswire.com/news-release/2025/08/06/3128280/0/en/Cardurion-Pharmaceuticals-Completes-Enrollment-in-Phase-2-CYCLE-Trials-Evaluating-CRD-750-a-Novel-PDE9-inhibitor-in-Heart-Failure.html

Prisidio Applauds AARP's Launch of Member-Exclusive Digital Vault to Combat Fraud and Preserve Legacies

Tue, 29 Jul 2025 14:07:16 GMT

Why More Americans Are Turning to Digital Vaults to Protect Themselves and Their Legacy

With online scams and data security incidents on the rise, more Americans – especially older adults – are taking proactive steps to store and share their most sensitive information using secure methods. A fast-growing solution is the digital vault: a secure, cloud-based platform for storing and sharing everything from wills and health directives to insurance documents and passwords.

AARP’s Fraud Watch Network found that 4 in 10 Americans have lost money to scams or had personal data compromised. The FBI's 2024 Internet Crime Report confirmed the trend, reporting $16.6 billion in total losses, with adults over 60 suffering the highest number of complaints and financial harm.

To help address these growing risks, AARP is making available a new product subscription which members can add-on to their membership. Prisidio, an AARP AgeTech Collaborative™ participant, created a digital vault for AARP members that provides a centralized and secure solution for individuals and families to collect and share their most vital documents and information in a more secure way, something that becomes increasingly important as we age. The AARP Digital Vault – powered by Prisidio – can store financial information, legal agreements, mortgage deeds, medical records, plus pictures and videos to ensure loved ones know where to find them when they need to.

“A digital vault isn’t just about convenience—it’s about peace of mind and preparedness,” said Sami Hassenyeh, Executive Vice President of Digital Strategy, at AARP. “Today, we offer the digital vault created by Prisidio as a solution that helps members protect what matters most in today’s increasingly digital world.”

AARP’s Digital Vault platform goes beyond simple cloud storage. It uses bank-level encryption, smart categorization, and allows users to designate trusted contacts who can access their vault. Whether it’s for estate planning, caregiving coordination, or natural disaster preparedness and daily peace of mind, digital vaults offer a modern way to manage life’s essential information.

Read more here: https://www.aarp.org/press/releases/2025-07-30-securing-important-documents-digital-vaults/

Genascence Announces U.S. Food and Drug Administration Grants Regenerative Medicine Advanced Therapy Designation to GNSC-001 for Knee Osteoarthritis (OA)

Thu, 17 Jul 2025 14:07:16 GMT

Genascence Corporation (“Genascence”), a clinical-stage biotechnology company revolutionizing the treatment of prevalent musculoskeletal diseases with gene therapy, today announced that the U.S. Food and Drug Administration (FDA) has granted the Regenerative Medicine Advanced Therapy (RMAT) designation to GNSC-001, a potential first-in-class gene therapy blocking interleukin 1 (IL-1) for the treatment of knee osteoarthritis (OA).

GNSC-001 is a genetic medicine – a recombinant adeno-associated viral vector expressing an optimized human interleukin-1 receptor antagonist (IL-1Ra), a naturally occurring protein that blocks IL-1 signaling. IL-1 is considered one of the key mediators involved in the pathogenesis of OA, causing inflammation, joint pain, and cartilage destruction. GNSC-001 is designed to offer long-term, sustained inhibition of IL-1 following a single intra-articular injection into the affected joint.

“GNSC-001 is the first IL-1 inhibitor for OA that has been shown to generate IL-1Ra expression levels that maintain therapeutic thresholds long-term following a single administration to inhibit pathogenic IL-1. The FDA RMAT designation for GNSC-001 underscores the strength of the clinical data to date, recognizing its potential to transform the treatment paradigm for OA,” said Thomas Chalberg, Ph.D., founder and CEO of Genascence. “With the RMAT designation for GNSC-001, we look forward to working closely with the FDA as we seek to accelerate late-stage clinical development of GNSC-001 so we can bring a new treatment option to people suffering from this incapacitating, disabling disease.”

Read more here: https://www.businesswire.com/news/home/20250716308556/en/Genascence-Announces-U.S.-Food-and-Drug-Administration-Grants-Regenerative-Medicine-Advanced-Therapy-Designation-to-GNSC-001-for-Knee-Osteoarthritis-OA

Astrocyte Pharmaceuticals Announces Milestones in the Fight Against Concussions: Launch of Phase 2 Clinical Trial and New $3M NIH Grant

Tue, 17 Jun 2025 14:07:16 GMT

Astrocyte Pharmaceuticals Inc., a clinical-stage biotechnology company today announced two major milestones that could change the way we protect brains from the damage caused by concussions and repeat head impacts - one of the most pressing health concerns for athletes, military personnel, and families around the world.

The company has dosed the first patient in its Phase 2 clinical trial in athletes who suffer concussions during competitive play. This trial, conducted in Australian football players, will test whether AST-004 delivered shortly after a concussion can lessen the deleterious effects on the brain and speed recovery. In addition, the company has been awarded a highly coveted $3M grant from the U.S. National Institutes of Health (NIH) to accelerate the development of an easy-to-use oral version of AST-004 in order to make the drug more readily available to patients and athletes.

A First-of-Its-Kind Drug for Concussion Protection

AST-004 is the first drug to show the ability in preclinical studies to protect the brain from the harmful effects of both mild and severe brain injuries. It is designed to preserve and protect brain function at the cellular level, limiting the short and long-term damage that can occur after head trauma.

“The world has searched for a way to reduce the brain damage caused by concussions - and now we’re seeing that possibility with AST-004,” said Theodore Liston, Ph.D., Vice President of Research at Astrocyte Pharmaceuticals. “In our early research, the drug consistently protected the brain in multiple models of concussion and head injury. With the support of the NIH and the launch of our Phase 2 clinical trial, we are now one step closer to getting this potential solution into the hands of those who need it most.”

Read more here: https://www.globenewswire.com/news-release/2025/06/17/3100467/0/en/Astrocyte-Pharmaceuticals-Announces-Milestones-in-the-Fight-Against-Concussions-Launch-of-Phase-2-Clinical-Trial-and-New-3M-NIH-Grant.html

Grove Biopharma Closes $30 Million Series A Financing to Advance Bionic Biologics™, a New Therapeutic Modality

Wed, 23 Apr 2025 14:07:16 GMT

Grove Biopharma, a private biotechnology company pioneering its Bionic Biologics™ platform to develop therapies targeting previously intractable intracellular disease targets, today announced the close of a $30 million Series A financing. The round was led by DCVC Bio with participation from Eli Lilly and Company, InVivium Capital, Walder Ventures, Gradiant Corporation, Mansueto Investments, and others. They join existing seed supporters, including Portal Innovations, where Grove was incubated. Proceeds will be used to further advance Grove Biopharma’s proprietary platform and drive its lead oncology programs towards the clinic.

Bionic Biologics represent a novel therapeutic modality that integrates principles of biologic and synthetic design. This innovative platform enables the targeting of well-validated yet previously intractable disease drivers, unlocking new possibilities for therapeutic intervention. Bionic Biologics combine advancements in precision polymer chemistry with the latest tools of medicinal chemistry, peptide chemistry, AI/ML driven computational chemistry and protein engineering. The result is an integrated platform capable of designing fully synthetic, cell-penetrant, protein-scale molecules that solve protein-scale problems.

“At Grove, we are focused on developing therapeutics for well-understood but historically intractable disease targets, with the goal of delivering better options for patients living with serious illnesses where few, if any, effective therapies exist,” said Geoffrey Duyk, M.D., Ph.D., Co-founder and CEO at Grove. “We believe our Bionic Biologics platform represents a true paradigm shift for drug development, enabling us to rapidly develop molecules that can selectively inhibit or degrade even the most challenging intracellular drug targets. We are deeply grateful to our seed and Series A investors for their ongoing confidence and support as we advance this exciting new technology to patients.”

Read more here: https://www.businesswire.com/news/home/20250423701255/en/Grove-Biopharma-Closes-%2430-Million-Series-A-Financing-to-Advance-Bionic-Biologics-a-New-Therapeutic-Modality

Worth Secures $25M Investment Led by TTV Capital, Driving Major Enterprise Growth, Expanding Workflow Automation Solutions

Tue, 11 Mar 2025 14:07:16 GMT

Led by industry veterans Sal Rehmetullah and Suneera Madhani, Worth is a strong force in fintech, helping lead enterprises scale faster with streamlined and automated onboarding and underwriting.

Worth, the all-in-one, fintech platform for onboarding and underwriting workflow automation, celebrates its leading position in the industry with with a $25 million investment led by TTV Capital and the rapid adoption of its AI-powered solutions by leading enterprises. The investment will accelerate the company's expansion, further enhance its cutting-edge technology and scale its services to large enterprise clients needing robust onboarding and underwriting workflow automation solutions.

Enterprises are often held up by time-consuming underwriting and onboarding processes; coupled with outdated systems that struggle to flag risk accounts efficiently, businesses are searching for solutions to streamline operations. Worth’s innovative platform leverages a proprietary database of over 242 million small businesses and analyzes 1,100+ data points in real time to drive industry-high match rates and seamless pre-fill capabilities. This enables enterprises to make smarter, faster underwriting decisions with unparalleled accuracy. With instant verification, streamlined compliance, tailored workflows, centralized case management and automated data population, Worth is an essential tool for fintechs, banks, lenders and other financial institutions to enhance risk management, streamline onboarding, accelerate growth and stay competitive in today’s market.

In addition to capital led by TTV Capital, Worth has financial backing collectively from mission-driven investors and financial partners supporting its growth, including Silicon Valley Bank, Ingeborg, Florida Funders, Deep Work Capital and Florida Opportunity Fund. These partners drive innovation and market expansion, with Deep Work Capital and Florida Opportunity Fund fueling Florida’s startup ecosystem, Florida Funders backing high-growth tech companies and Ingeborg, founded by Olivia Walton, investing in women-led and mission-led businesses.

Read more here: https://www.globenewswire.com/news-release/2025/03/11/3040801/0/en/Worth-Secures-25M-Investment-Led-by-TTV-Capital-Driving-Major-Enterprise-Growth-Expanding-Workflow-Automation-Solutions.html

Genascence Announces Six-Month Results from Phase 1b DONATELLO Trial Indicating GNSC-001 Was Safe and Well Tolerated Across Multiple Dosing Arms

Thu, 09 Jan 2025 14:07:24 GMT

Genascence Corporation ("Genascence"), a clinical-stage biotechnology company revolutionizing the treatment of prevalent musculoskeletal diseases with gene therapy, today announced positive interim safety and biomarker results from the Phase 1b DONATELLO clinical trial evaluating GNSC-001. GNSC-001 is an investigational AAV gene therapy product for knee osteoarthritis (OA) that encodes interleukin 1 receptor antagonist (IL-1Ra), a potent inhibitor of interleukin 1 (IL-1). Data from the six-month analysis demonstrated acceptable safety and tolerability across all doses tested, along with encouraging biomarker data.

"These six-month interim results mark a critical milestone in our mission to transform the treatment paradigm for osteoarthritis," said Jeymi Tambiah, M.D., chief medical officer of Genascence. "The safety profile and sustained IL-1Ra expression data underscore the promise of GNSC-001 as a potential one-time gene therapy for this debilitating condition. The results from DONATELLO will guide discussions with regulatory authorities as Genascence prepares to initiate a Phase 2 trial focused on clinical efficacy."

Read more here: https://www.prnewswire.com/news-releases/genascence-announces-six-month-results-from-phase-1b-donatello-trial-indicating-gnsc-001-was-safe-and-well-tolerated-across-multiple-dosing-arms-302345061.html

Pikmykid Acquires Visitu to Enhance School Visitor Management Solutions

Wed, 08 Jan 2025 20:06:56 GMT

Pikmykid Acquires Visitu to Enhance School Visitor Management Solutions

Pikmykid, the leading school safety platform, is proud to announce the acquisition of Visitu, a cutting-edge visitor management system. This strategic acquisition bolsters Pikmykid's capabilities in visitor management while advancing its mission to enhance school safety and operational efficiency.

As schools increasingly focus on safety, the addition of Visitu's visitor and attendance management tools enables Pikmykid to offer a comprehensive solution for managing every aspect of campus safety. From the moment staff, students, parents, volunteers, visitors, and contractors enter the campus to the time students leave safely at the end of the day, Pikmykid now provides an end-to-end platform that prioritizes safety and efficiency.

"Our school's operations and facilities teams are excited for the potential of even smoother and more effective integration between Visitu and Pikmykid, two solid systems we use to enhance safety at our campuses," said Eric Neumann, Sr Director of School Operations at Rocketship Charter Schools. "We look forward to continued partnership to further improve our school arrival and dismissal systems, campus security, and overall staff, family, and student experiences!"

"Acquiring Visitu is a transformative milestone in our mission to redefine school safety," said Saravana Pat Bhava, CEO of Pikmykid. "With the power of one unified platform, we are now able to provide schools with an integrated solution that enhances security while elevating the visitor and community experience"

"Empowering schools with tools that enhance staff efficiency and parent engagement is critical to improving student outcomes," added Chitra Kanagaraj, COO. "By uniting all safety and engagement tools, we enable schools and districts to focus on what matters most—student success."

Read more here: https://www.prnewswire.com/news-releases/pikmykid-acquires-visitu-to-enhance-school-visitor-management-solutions-302345647.html

Apple Arcade launches into 2025 with 10 new games, including PGA TOUR Pro Golf

ken@deepworkcapital.com (Ken Hall) — Wed, 08 Jan 2025 20:00:20 GMT

PGA TOUR Pro Golf by HypGames, Inc.

PGA TOUR Pro Golf offers an immersive golf experience designed for fans of the sport. Featuring iconic PGA TOUR locations like Pebble Beach Golf Links and Harbour Town Golf Links, players can participate in competitive head-to-head matches or thrilling tournaments against other players, along with sharpening their skills through practice rounds. With true-to-life courses inspired by those used by professional golfers, the game brings the excitement of the sport to life across iPhone, iPad, Mac, Apple TV, and Apple Vision Pro.

Source: https://www.apple.com/newsroom/2025/01/apple-arcade-launches-into-2025-with-10-new-games-including-pga-tour-pro-golf/

Ken Hall, Partner, Honored in Orlando Business Journal's Class of 2025 40 Under 40

ken@deepworkcapital.com (Ken Hall) — Tue, 07 Jan 2025 19:54:16 GMT

We're thrilled to see Ken Hall honored on Orlando Business Journal's 2025 40 Under 40 list!

On top of being an invaluable part of the DeepWork Capital team, Ken has been a robust connector and facilitator within the innovation ecosystem. What he does exemplifies his proclivity to create win-win scenarios with all constituents.

Source: https://www.bizjournals.com/orlando/news/2025/01/07/40-under-40-honorees-central-florida-part-2-awards.html

TAO Connect Acquired by UpLift Health Technologies

ken@deepworkcapital.com (Ken Hall) — Tue, 12 Mar 2024 18:02:13 GMT

With its acquisition of TAO Connect, UpLift now serves over 170 enterprise customers in the U.S. and Canada. It covers four million people, including more than two million students at more than 120 higher education institutions.

UpLift, a behavioral health company, announced Monday that it has acquired TAO Connect, a mental health company for higher education organizations. Tampa, Florida-based UpLift offers virtual access to talk therapy, psychiatry and medication management services. It has a national network of nearly 2,000 providers and accepts insurance, including from Aetna, Cigna and UnitedHealthcare. Clearwater, Florida-based TAO Connect provides higher education institutions with online interactive programs and tools designed to tackle mental health. It offers modules on a variety of topics, including how to manage the first year of college, how to improve focus, and sexual assault prevention.

UpLift’s acquisition of TAO Connect was a mix of cash and stock, but the companies did not share the purchase price. The companies are now launching TAO by UpLift, which gives institutions “access to a comprehensive higher ed mental healthcare solution, and the continuity of care designed to complement institutions’ counseling service offerings, all covered by insurance,” according to the announcement.

With the acquisition, UpLift now serves over 170 enterprise customers in the U.S. and Canada. It covers four million people, including more than two million students at more than 120 higher education institutions.

“The lack of access to affordable behavioral healthcare is a key driver in America’s mental health crisis and our students are struggling — increasingly anxious, depressed, and battling loneliness all while facing the pressure of academia,” said Kyle Talcott, founder and CEO of UpLift, in an email. “TAO is already on the ground, a 10-year-old, tried and proven, higher ed company with a clinically validated mental healthcare solution providing self-guided tools and resources for students that complements institutions’ counseling service offerings. “

When asked how TAO Connect will fit into UpLift’s operations, Talcott said the company is “thinking about it as business-as-usual in that we are maintaining the great momentum the TAO team has had with serving TAO’s higher education clients.” He added that UpLift has retained most of the TAO team.

“We do have plans for both near and long-term product integrations — for example, creating synergies through seamless student referrals and care escalation processes — which our Product and Engineering teams are scoping,” Talcott said. “We are of course beginning to offer UpLift’s clinical services to higher education institutions.”

The acquisition comes at a time when 77% of college students battle mental health problems and 53% are unable to receive care, according to the American College Health Association. In addition, a recent survey looked at the reasons students didn’t seek care and found that 51% thought it was too expensive, 27% said wait times were too long and 27% said they couldn’t find care.

Dr. Sherry Benton, founder of TAO Connect, said the company has shared goals with UpLift, and the acquisition helps achieve those goals.

“Like UpLift, TAO Connect was conceived to fulfill the increasing demand for more accessible and better mental healthcare treatment options and solutions, including telehealth,” Benton said in an email. “As part of UpLift, we can now be more effective in servicing the higher ed market’s unmet needs, providing a continuum of mental health care that includes team-based therapy and psychiatry.”

UpLift’s acquisition of TAO Connect comes after the company acquired Minded in November. Minded is an online psychiatry provider focused on women. In July, UpLift also announced it raised $10.7 million in Series A funding, bringing its total funding to more than $22 million.

Source: https://lnkd.in/eyeyZZZa

Ben Patz Honored By Orlando Business Journal As A 2023 Power Player of the Year

ken@deepworkcapital.com (Ken Hall) — Thu, 09 Nov 2023 20:17:17 GMT

Ben Patz Honored By Orlando Business Journal As A 2023 Power Player of the Year

Category

Dealmaker

Your formal title:

CEO

Company name:

DeepWork Capital

No. of employees you manage

Your no. of years in the industry

Your 2024 outlook

The best year yet in a series of incredible years.

What's a fun or little-known fact about you

Most think Ben is the tallest VC in Florida ... but he isn't.

Talk about your most significant deal in the past year and how did you get it done?

The firm has invested in over 30 incredible Florida companies over the past year and each required a special touch including finding and recruiting founders of exceptional vision that needed some convincing to take advantage of our expertise, investing with world class co-investors that would come to appreciate our value, and adding additional leaders to a business' team that changed everything. All required a mix of insight, passion, and grit and Coleman's Law #19 "an ability to get the job done".

Looking back at a deal that got away in your career, what would you have done differently?

Listen more, pontificate less, reflect first on the steps needed to win an opportunity before reflecting on the steps necessary to implement.

Read more : https://www.bizjournals.com/orlando/c/2023-power-players-central-florida/20843/benjamin-patz.html

Announcing Ken Hall's Promotion to Principal

Thu, 05 Jan 2023 21:02:24 GMT

DeepWork Capital promotes Ken Hall to Principal

Dear DeepWork Community,

It is with great pleasure that we announce today the promotion of Ken Hall to the position of Principal at DeepWork Capital. Since joining the team in June 2021, Ken has demonstrated the ability to source investments, support portfolio companies, conduct due diligence, lead transactions, and cultivate relationships within the innovation community. Ken has earned this promotion with relentless hard work and embodiment of DeepWork values. In his year and a half with DeepWork, Ken has become an integral part of the team and has played a pivotal role in our efforts to serve our investors and entrepreneurial community. As high as our expectations were of Ken when he joined the team, he has exceeded those expectations and made a profound impact on our firm, our portfolio companies, and our community.

Please join us in our congratulations to Ken on his promotion to Principal!

Sincerely,

The DeepWork Capital Team

About Ken Hall

A member of DeepWork since 2021, Ken Hall is responsible for sourcing new deals, leading investment transactions, and actively supporting DeepWork portfolio companies. Ken has sourced and led various investments for both DeepWork Capital and the Florida Opportunity Fund, including Mobilo, Recuro Health, Home Lending Pal, and Quottly. Prior to joining DeepWork, Ken worked in New York City for IBM and held multiple roles in corporate development, mergers & acquisitions, and corporate venture capital. Ken has additional venture capital experience as an advisor to 1843 Capital and family offices from the founding families of both Motorola and The Carlyle Group. In addition to his work at DeepWork Capital, Ken is the Chair of Startups & Growth for the Orlando Tech Community, an advisory board member for IBM Hyperprotect and Synapse Florida, an organizer of Startup Weekend Orlando (SWORL), a frequent guest lecturer at Rollins College, UCF, and Full Sail University, and a mentor at leAD Sports & Health Tech, NewChip, Founders Institute, and UCF Incubator.

Kathy Chiu to Receive BioFlorida Leadership Award

ken@deepworkcapital.com (Ken Hall) — Mon, 07 Nov 2022 14:07:16 GMT

Kathy Chiu to Receive BioFlorida Leadership Award

DeepWork Capital is pleased to announce that managing partner Kathy Chiu will receive the 2022 BioFlorida Leadership Award at BioFlorida's 25th Annual Conference.

The BioFlorida Leadership Award recognizes the BioFlorida volunteer who has taken on a leadership role within the organization, dedicated significant time to BioFlorida's mission, and has acted as a true ambassador to BioFlorida and the industry.

Chiu co-founded DeepWork Capital, an Orlando-based company, in 2015 to help close the funding gap in Florida's innovation economy. DeepWork Capital is a rare multi-disciplinary early-stage venture capital fund in the state with life science capabilities. Its selection as the investment manager enables FOF to process life science investments, a development welcomed by BioFlorida. Chiu was instrumental in building up DeepWork's Life Science capabilities and led the firm in its investment in HCW Biologics (NASD: HCWB), which went public in 2021.

At the 2022 BioFlorida Annual Conference, Chiu served as judge of BioPitch, a pitch competition that connects life science companies to investors. Chiu's dedication helped the organization expand its network to include a record-breaking 25+ investors and 55 applicants, as well as using her experience to implement key improvements to the BioPitch competition to address the needs of participants.

HypGames Partners with Niantic to Launch NBA All World

ken@deepworkcapital.com (Ken Hall) — Tue, 28 Jun 2022 23:10:57 GMT

HypGames to Partner with Niantic on New Mobile Game

HypGames, an Orlando based mobile game developer and DeepWork Fund I portfolio company, will partner with Niantic on the launch of NBA All-World.

NBA All-World promises a “real world metaverse” in which user geolocation data is used to find, challenge, and recruit current NBA players to their team. The game also taps into the fashion and lifestyle elements of the league, with players able to outfit players in their teams with custom NBA apparel.

“NBA All-World represents an industry first in sports games, as an original, real-world AR game that will appeal to casual and core NBA fans alike,” said Marcus Matthews, senior producer at Niantic. “We’re creating and designing a game that empowers players to represent where they’re from and showcase the culture of their neighbourhood.”

Matt Holt, head of consumer products at the NBA, added: “Through our partnership with Niantic, NBA All-World will provide fans across the globe the opportunity to fully immerse themselves into the energy and excitement of the NBA. “Evident in the name of the game itself, we look forward to engaging with our fans around the world through this captivating experience.”

https://nianticlabs.com/blog/unveiling-nba-all-world/?hl=en

Mitchel Laskey to Receive TIECON's Angel Investor of the Year

ken@deepworkcapital.com (Ken Hall) — Mon, 20 Jun 2022 23:23:41 GMT

DeepWork Managing Partner Mitchel Laskey to Receive TIECON's Angel Investor of the Year

DeepWork Capital is pleased to announce that managing partner Mitchel Laskey will receive TIECON Tampa Bay’s Angel Investor of the Year as part of the TIETAN awards in September 2022.

Mitchel Laskey is a co-founder and managing partner at DeepWork, has led countless investments through the firm, has held board positions at numerous startups, and remains extremely active throughout the startup community in Florida. In addition to being a leader at DeepWork, Laskey is also on the Board of Directors for Cogent Bank, which focuses on providing flexible, innovative and forward-thinking services throughout its eight locations across Florida.

Previously, on the entrepreneur side, Laskey said the highlight of his career was when he served as the CEO and founder of Orlando-based Dynamic Healthcare Technologies Inc. and had the opportunity to testify before Congress regarding Homeland Security issues.

Laskey will receive the TIETAN award during the annual marquee event that spotlights entrepreneurs from all over the world.

Read more : https://stpetecatalyst.com/tietan-awardee-mitchel-laskey-of-deepwork-capital/

Stax to Become Fintech's Newest Unicorn with Latest Funding Round

ken@deepworkcapital.com (Ken Hall) — Tue, 08 Mar 2022 22:47:29 GMT

Co-founders and sister-and-brother duo Suneera Madhani and Sal Rehmetullah lead their company to $1B+ valuation, making history for minority founders and leaders everywhere

Stax, the Orlando-based financial technology company previously known as Fattmerchant, on March 8 announced it closed a $245 million investment round. The capital infusion not only will let Stax keep up its rapid growth, but it also puts the valuation of the company at $1 billion.

Since it was founded in 2014, Stax’s payment processing technology has powered more than $23 billion in transactions for businesses. The company last year made a majority investment in Canadian billing management software firm Fusebill, and the influx of capital will enable Stax to further grow its international customer base, Madhani said. “A huge piece of this investment is to take us international.”

Investors in the round included Knoxville, Tennessee-based Greater Sum Ventures, which in 2020 made a majority investment in Stax, as well as Boston-based HarbourVest Partners and Frisco, Texas-based Blue Star Innovation Partners. Blue Star CEO and founder Rob Wechsler will join Stax’s board of directors.

Meanwhile, Stax has served as a success story for Central Florida’s entrepreneurial community. In its early days, the company used local resources like accelerator Starter Studio or the Rollins College Venture Plan Competition to access coaching, funding and exposure.

One of the first investors in the company was Orlando-based venture capital firm DeepWork Capital LLC. It’s not surprising to see Stax hit the $1 billion valuation milestone, DeepWork Managing Partner Mitchel Laskey told Orlando Inno. “The team at Stax is a team that has delivered every single month for as long as we’ve known them, which is back to 2015.”

DeepWork Capital first invested in Stax in 2015 through Fund I. Our team at DeepWork view this accomplishment as an amazing milestone for the phenomenal team at Stax, the City of Orlando, and diverse teams and female founders everywhere.

Read More:

    https://fortune.com/2022/03/09/stax-ceo-suneera-madhani-fintech-unicorn/

    https://www.bloomberg.com/news/articles/2022-03-08/ceo-of-unicorn-stax-says-she-ll-go-head-to-head-with-stripe

    https://www.businesswire.com/news/home/20220308005074/en/Stax-to-Become-Fintechs-Newest-Unicorn-with-Latest-Funding-Round

    https://www.bizjournals.com/orlando/news/2022/03/08/orlando-stax-hits-1b-valuation-after-closing-bi.html

Urban SDK Receives Enterprise Florida's 2021 Entrepreneur and Job Growth Award

ken@deepworkcapital.com (Ken Hall) — Thu, 17 Feb 2022 00:24:37 GMT

Jackson ville-based startup recognized with Enterprise Florida's "Entrepreneur and Job Growth" award

Enterprise Florida presented Urban SDK with the EFI Entrepreneur and Job Growth Award during its most recent Board of Directors meeting in Tallahassee. The Jacksonville-based data analytics and visualization company was recognized for its commitment to job growth within the state, as well as its work showcasing Florida as a global leader in innovation.

The Enterprise Florida Entrepreneur and Job Growth Award was established by Enterprise Florida in 2019 to recognize Florida businesses that have created jobs and invested in communities across the state.

"This is a proud moment for our team, customers and investors. Thank you to Governor DeSantis, EFI Board, the Florida Opportunity Fund and DeepWork Capital. Our success over the last 3 years would not be possible without your continuous efforts to make Florida the premier business destination in the world." - Drew Messer, CEO of Urban SDK

Fore more information, please visit:

https://www.globenewswire.com/news-release/2022/02/15/2385609/0/en/Urban-SDK-Receives-the-EFI-Entrepreneur-and-Job-Growth-Award.html

AbFero Pharmaceuticals acquired by Pharmacosmos Group

ken@deepworkcapital.com (Ken Hall) — Fri, 12 Nov 2021 00:28:31 GMT

DeepWork Fund II portfolio company acquired for total proceeds of $225M

Our team is happy to announce that AbFero Pharmaceuticals, a DeepWork Capital Fund II portfolio company, has been acquired by Pharmacosmos Group.

AbFero Pharmaceuticals Inc. is a clinical stage pharmaceutical company developing best-in-class oral iron chelators for the treatment of diseases of iron-overload (specifically, transfusional iron overload, TIO). The Company is focused exclusively on iron as a therapeutic target and is initially focused on advancing its candidate, SP-420, in the treatment of iron-overload conditions. The Company's technology platform was invented by Professor Ray Bergeron of the University of Florida.

DeepWork first invested in AbFero Pharmaceuticals through Fund II in August 2020 and again in March 2021. DeepWork invested in AbFero alongside UF Innovate and Longwall Ventures. The combination of AbFero and Pharmacosmos, a leader in developing treatments for patients suffering from iron deficiency and iron deficiency anemia, will accelerate the development of SP-420 and help the companies deliver much-needed therapeutic options to patients.

https://www.prnewswire.com/news-releases/pharmacosmos-group-acquires-boston-based-clinical-stage-abfero-pharmaceuticals-inc-301422092.html

HCW Biologics Inc. Completes $56.0 Million Initial Public Offering

ken@deepworkcapital.com (Ken Hall) — Thu, 22 Jul 2021 21:52:50 GMT

HCW Biologics Inc. Completes $56.0 Million Initial Public Offering

Our team is happy to announce that HCW Biologics, a DeepWork Fund II portfolio company, completed an initial public offering (IPO) on 7/20/21. HCW Biologics, a Miramar, FL company, is now trading on the NASDAQ under the ticker “HCWB”.

You can find all relevant information about the company in its public filing with the SEC. The biopharmaceutical company is focused on developing transformative immunotherapies to disrupt the link between chronic, low-grade inflammation and age-related diseases. The team, led by Hing C. Wong, Ph.D., believes age-related low-grade chronic inflammation is a significant contributing factor to several chronic diseases and conditions. HCW believes that they have the potential to provide an innovative treatment to these age-related diseases.

The IPO is a meaningful milestone for the team at HCW, our team and investors at DeepWork, and the greater Florida community.

https://investors.hcwbiologics.com/news-releases/news-release-details/hcw-biologics-inc-announces-pricing-560-million-initial-public

PikMyKid Receives Growth Equity Investment from Growth Street Partners

ken@deepworkcapital.com (Ken Hall) — Thu, 06 May 2021 15:40:41 GMT

PikMyKid, the Leading School Dismissal Management SaaS Platform, Announces Growth Equity Investment from Growth Street Partners

Growth Street Partners has announced its minority growth equity investment in PikMyKid to grow the SaaS platform, expand its team, and increase adoption.

Co-Founder and CEO of PikMyKid Saravana Pat Bhava notes that "the value [Growth Street has] already added to the company has truly blown us away, and we're just getting started."

Congratulations to the PMK and Growth Street teams!

To learn more, please visit: https://www.prnewswire.com/news-releases/pikmykid-the-leading-school-dismissal-management-saas-platform-announces-growth-equity-investment-from-growth-street-partners-301284763.html.

Fattmerchant Receives Majority Investment from Greater Sum Ventures

Thu, 03 Dec 2020 15:09:20 GMT

Fattmerchant, DeepWork Capital Fund I portfolio company, to receive majority investment from Greater Sum Ventures

Greater Sum Ventures (GSV), a growth equity firm and family office, has announced a majority investment in Fattmerchant to accelerate the startup’s growth. DeepWork first invested in Fattmerchant in November 2015.

CEO Suneera Madhani notes that “we’re gratified by GSV’s show of confidence and look forward to working with this experienced team to continue our explosive organic growth.” Madhani, President Sal Rehmetullah, and the founding team will continue to lead Fattmerchant through this new chapter.

Congratulations to both the Fattmerchant and GSV teams!

To learn more, please visit:

https://www.globenewswire.com/news-release/2020/12/01/2137737/0/en/UPDATE-Greater-Sum-Ventures-Makes-Majority-Investment-in-Payments-Company-Fattmerchant.html.

EternaTear Closes Oversubscribed Series A

ken@deepworkcapital.com (Ken Hall) — Wed, 11 Nov 2020 16:15:29 GMT

EternaTear Closes Oversubscribed Series A

EternaTear has announced its successful completion of a $4.9M Series A financing round.

The oversubscribed round was led by Carolina Angel Network and Keiretsu Forum, with additional participation from DeepWork Capital, Band of Angels, Duke Angel Network, Keiretsu Capital, and other angel investors. With this new capital, EternaTear moves its product closer to market, toward completion of a clinical marketing study, and toward FDA OTC registration.

For more information, please visit: https://www.bizjournals.com/triangle/news/2020/10/07/raleigh-drugmaker-closes-on-series-a-fund.html.